Your Messages Inbox
Your Article Summary
See Latest Articles(Click the title below to leave the MDLinx Network and go to the Journal's Website)
Patients taking VIMOVO showed improved UGI tolerability assessments as compared to EC naproxen
AstraZeneca, 10/29/09
AstraZeneca and POZEN Inc. announced results from an analysis of two pivotal Phase III studies of VIMOVO, formerly known as PN 400, and enteric–coated naproxen alone in patients at risk for NSAID–associated ulcers.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09
Bayer CropScience signs Agreement with GVK Biosciences on early-stage research projects
BayNews International, 11/25/09
Reports Rate Ambulatory EHR Software
HealthDataManagement, 11/25/09
Article Search
Sponsor